SCHEMBL3012253

SCHEMBL3012253

Cc1cccc(Cc2csc(N3CCC(S(=O)(=O)c4ccc(F)c(Cl)c4)CC3)n2)c1

nearest known ligand 0.36

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
SCN8A Q9UQD0 7/20 0.36
SCN1A P35498 6/20 0.36
DNM1L O00429 4/20 0.34
PKM P14618 1/20 0.34
PKLR P30613 1/20 0.34
DRD2 P14416 1/20 0.34
HTR2A P28223 1/20 0.34
HTR2C P28335 1/20 0.34
KCNH2 Q12809 1/20 0.34
USP2 O75604 1/20 0.34
MAPT P10636 1/20 0.34
RECQL P46063 1/20 0.34
HSD17B10 Q99714 1/20 0.34
GBA1 P04062 1/20 0.34
TP53 P04637 1/20 0.34
THRB P10828 1/20 0.33
RAB9A P51151 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3009705 0.92 DNM1L (0.35) SCN8ASCN1ADNM1LDRD2HTR2A
SCHEMBL3019996 0.92 SCN8A (0.37) SCN8ASCN1ADNM1LHTR2AMAPT
SCHEMBL3001961 0.91 HTR2A (0.34) PKMPKLRDRD2HTR2AHTR2C
SCHEMBL3002470 0.91 TP53 (0.38) SCN8ASCN1ADNM1LDRD2HTR2A
SCHEMBL3007012 0.90 GBA1 (0.38) DNM1LDRD2HTR2AHTR2CKCNH2
SCHEMBL3013788 0.90 HTR2A (0.39) DNM1LPKMPKLRDRD2HTR2A
SCHEMBL3009255 0.90 HTR2A (0.37) SCN8ASCN1APKMPKLRDRD2
SCHEMBL3018787 0.90 RAB9A (0.39) DNM1LHTR2AMAPTGBA1RAB9A
SCHEMBL3020188 0.89 DNM1L (0.37) SCN8ASCN1ADNM1LHTR2AMAPT
SCHEMBL3013270 0.89 MAPT (0.44) SCN8ASCN1APKMUSP2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA SCN8A 2162/4885SCN1A 185/4885DNM1L 180/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.